STYRON™ 2678 MED Polystyrene Resins can be used for a variety of medical device applications including clear packaging, diagnostic components, petri dishes and housings for test kits.
Highlights of the resin material include excellent transparency (approx. 90% transmission), stiffness, rigidity and heat resistance. Properties supporting medical device applications include biocompatibility, sterilization stability, and chemical resistance to fight infection. The material may also be processed further with secondary operations such as solvent bonding, welding and laser marking, typical for medical devices.
“There’s a growing need - especially within medical packaging – for a medical grade polymer that performs well, protects the product, and provides an added degree of safety,” said Ben Porter, technical service & development engineer, Trinseo, Netherlands. “STYRON™ 2678 MED Polystyrene Resin provides customers with an ideal and economical solution and an alternative to general purpose food grade polystyrene.”
Trinseo has served the global medical devices market with high performance plastics for single- and multiple-use devices and equipment housings for nearly three decades. The company offers worldwide production and fulfillment, recently announcing its medical compounding capability in Asia Pacific to complement existing compounding in Europe and North America.
STYRON™ 2678 MED Polystyrene Resin expands Trinseo’s offering of transparent materials for medical applications.
About Trinseo
Trinseo (NYSE: TSE), a specialty material solutions provider, partners with companies to bring ideas to life in an imaginative, smart, and sustainability-focused manner by combining its premier expertise, forward-looking innovations and best-in-class materials to unlock value for companies and consumers.
From design to manufacturing, Trinseo taps into decades of experience in diverse material solutions to address customers’ unique challenges in a wide range of industries, including consumer goods, mobility, building and construction, and medical.
Trinseo’s approximately 3,400 employees bring endless creativity to reimagining the possibilities with clients all over the world from the company’s locations in North America, Europe, and Asia Pacific. Trinseo reported net sales of approximately $4.8 billion in 2021. Discover more by visiting www.trinseo.com and connecting with Trinseo on LinkedIn, Twitter, Facebook and WeChat.
Cautionary Note on Forward-Looking Statements
This press release may contain forward-looking statements including, without limitation, statements concerning plans, objectives, goals, projections, strategies, future events or performance, and underlying assumptions and other statements, which are not statements of historical facts or guarantees or assurances of future performance. Forward-looking statements may be identified by the use of words like "expect," "anticipate," "intend," "forecast," "outlook," "will," "may," "might," "see," "tend," "assume," "potential," "likely," "target," "plan," "contemplate," "seek," "attempt," "should," "could," "would" or expressions of similar meaning. Forward-looking statements reflect management’s evaluation of information currently available and are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Factors that might cause future results to differ from those expressed by the forward-looking statements include, but are not limited to, our ability to successfully execute our transformation strategy and business strategy; our ability to integrate acquired businesses; global supply chain volatility, increased costs or disruption in the supply of raw materials or increased costs for transportation of our products; the nature of investment opportunities presented to the Company from time to time; and those factors discussed in our Annual Report on Form 10-K, under Part I, Item 1A —"Risk Factors" and elsewhere in our other reports, filings and furnishings made with the U.S. Securities and Exchange Commission from time to time. As a result of these or other factors, our actual results may differ materially from those contemplated by the forward-looking statements. Therefore, we caution you against relying on any of these forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.